The results showed that Tagrisso reduced the risk of death by 51% compared to placebo in both the primary analysis and overall trial populations. The study also demonstrated a statistically significant and clinically meaningful improvement in overall survival compared to placebo in the adjuvant treatment setting.
Susan Galbraith, Executive Vice President of Oncology Research and Development at AstraZeneca, highlighted the significance of these findings, stating that Tagrisso's ability to halve the risk of death establishes it as a pivotal treatment for EGFR-mutated lung cancer. Galbraith emphasized the importance of early lung cancer diagnosis, testing for EGFR mutations, and treating all patients with an EGFR mutation with Tagrisso.
In addition to the adjuvant setting, Tagrisso is also being investigated in Phase III trials in the neoadjuvant resectable setting (NeoADAURA), the Stage IA2-IA3 adjuvant resectable setting (ADAURA2), and the Stage III locally advanced unresectable setting (LAURA). These studies aim to further explore the potential of Tagrisso in different stages and contexts of lung cancer treatment.
